TOT BIOPHARM International Company Ltd

Detailed Description

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. Its principal drug candidate is TAB008, which is in a Phase III clinical trial for the treatment of non-squamous non-small-cell lung cancer (nsNSCLC) and metastatic colorectal cancer. The company also develops TAA013 for HER2+ breast cancer; TAE020 for acute myeloid leukemia; TAB014 for wet age-related macular degeneration; TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, NSCLC, and gastric cancer; and TOZ309 for malignant brain tumor. In addition, it develops TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.